By Fineline Cube 
Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.
Partnership Framework & Strategic Focus
| Element | Details |
|---|---|
| Companies | Cygenta Biotech + Horicin Biotechnology |
| Technology | Mesenchymal Stromal Cell (MSC) therapeutic products |
| Collaboration Model | Cygenta provides comprehensive CDMO services |
| Scope | Full chain from pharmaceutical services to IND application support |
| Strategic Goal | Accelerate efficient clinical translation of regenerative medicine products |
Horicin Biotechnology Profile
Founded: 1999
Status: National High-Tech Enterprise
Core Business: New drug R&D and technical services
Therapeutic Focus Areas:
- Anti-cancer targeted drugs
- Central nervous system drugs
- Cardiovascular and cerebrovascular drugs
- Anti-infective drugs
- Gynecological drugs
- Digestive system drugs
- Topical medicines
R&D Capabilities: Covers chemical, traditional Chinese, and biological medicines
Cygenta Biotech Profile
Headquarters: Beijing
Facilities: >8,000 square meters of CGT (Cell and Gene Therapy) cGMP compliant facilities
Standards: Meet FDA, EMA, and NMPA regulatory requirements
Services: Manufacturing for plasmid, viral vector, and cell products from research grade to commercialization grade
Client Base: Gene and cell therapy companies requiring integrated manufacturing solutions
Strategic Rationale & Market Impact
Synergy Creation:
- Horicin’s Pipeline: Deep expertise in multiple therapeutic areas with MSC application potential
- Cygenta’s Infrastructure: State-of-the-art manufacturing capacity reduces development timelines
- Full Integration: End-to-end service eliminates gaps between R&D and clinical manufacturing
Market Context:
- MSC Market: Global MSC therapy market projected $15 billion by 2030, growing at 22% CAGR
- China Advantage: Regulatory support for cell therapy innovation accelerates clinical translation
- CDMO Demand: Domestic biotech companies increasingly outsourcing manufacturing to specialized providers
Competitive Positioning:
- First Mover: Among few China-based CDMOs offering complete MSC therapy services
- Quality Standards: Multi-regulatory compliance enables global clinical development pathways
- Scalability: 8,000+ sqm facility supports multiple parallel client programs
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the partnership’s execution, technology development timelines, and commercial prospects. Actual results may differ due to regulatory processes, technology transfer challenges, and competitive dynamics in the cell therapy CDMO market.-Fineline Info & Tech